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Transcription is coupled to repair in Escherichia coli
and in humans. Proteins encoded by the mfd gene in E.
coli and by the ERCC6/CSB gene in humans, both of
which possess the so-called helicase motifs, are required
for the coupling reaction. It has been shown that the
Mfd protein is an ATPase but not a helicase and accom-
plishes coupling, in part, by disrupting the ternary com-
plex of E. coli RNA polymerase stalled at the site of DNA
damage. In this study we overproduced the human CSB
protein using the baculovirus vector and purified and
characterized the recombinant protein. CSB has an
ATPase activity that is stimulated strongly by DNA;
however, it neither acts as a helicase nor does it disso-
ciate stalled RNA polymerase II, suggesting a coupling
mechanism in humans different from that in pro-
karyotes. CSB is a DNA-binding protein, and it also
binds to XPA, TFIIH, and the p34 subunit of TFIIE.
These interactions are likely to play a role in recruiting
repair proteins to ternary complexes formed at damage
sites.
Transcribed DNA is repaired preferentially in both mamma-
lian cells (1, 2) and E. coli (3). The preferential repair, to a large
extent, is due to the high rate of repair of the template (tran-
scribed) strand relative to the coding (nontranscribed) strand
and transcriptionally inactive DNA (2). Mutations in the mfd
gene in E. coli (4) and in the CSA1 and CSB genes in humans
(5) abolish preferential repair. The mechanism of action of the
Mfd protein and of transcription-repair coupling in E. coli has
been elucidated in considerable detail (6–8). However, at-
tempts at understanding transcription-coupled repair in hu-
mans have been frustrated by the lack of an efficient system for
transcription by RNA polymerase II in vitro and by the lack of
purified CSA and CSB proteins, which are known to be essen-
tial for coupling2 (9, 10).
The CSA (11) and CSB (12) genes have been cloned and
sequenced. CSA is a protein of 44 kDa and belongs in the
“WD-repeat” family of proteins (11, 13). The CSB protein has a
predicted size of 168 kDa, contains helicase motifs, and belongs
in the SWI/SNF family of proteins (12, 14, 15). Because of size,
sequence, and apparent functional similarities between CSB
and Mfd, it has been generally assumed that CSB may play a
role similar to that of Mfd (4, 16, 17). Hence the purification
and characterization of CSB were considered essential for un-
derstanding the phenomenon of transcription-coupled repair.
In this paper we describe the purification and characterization
of recombinant human CSB protein. ATPase activity was de-
tected with CSB protein, and this activity was characterized
with regard to allosteric effectors. Although our CSB was active
as indicated by its DNA binding and ATPase activities, it did
not remove a stalled RNA Pol II. While this work was in
progress Guzder et al. (18) reported that the yeast CSB homo-
log Rad26 protein is a DNA-dependent ATPase with no detect-
able helicase activity.
EXPERIMENTAL PROCEDURES
Plasmid Constructs—Plasmids for expression of TFIIE (19–21) and
TFIIF (22, 23) have been described previously. The ERCC6 gene cloned
into the vector Bluescript and designated pcBLsSE6 (12) was provided
by Dr. J. H. J. Hoeijmakers (Erasmus University). A HpaI site was
placed immediately upstream of the ATG initiation codon (59-AGAATG
to 59-AGAGTTAACATG) by site-directed mutagenesis (24) to facilitate
subcloning; this construct was designated pE6Hpa. To generate a tem-
plate for in vitro transcription-translation, the CSB gene was subcloned
as a HpaI-XbaI fragment from pE6Hpa into the SmaI-XbaI site of
pIBI24 (VWR Scientific, Inc.), which places the gene downstream from
the T7 promoter; this construct was designated pIE6. A construct in-
tended to produce a full-length CSB-MBP fusion protein was made by
inserting the HpaI-XbaI fragment from pE6Hpa into the XmnI-XbaI
site of pMal-c2 (New England Biolabs) and was designated pMALE6. A
construct for producing a fusion of GST protein with amino acids 528-
1222 of CSB was made by subcloning the internal EcoRI fragment of the
CSB gene into the EcoRI site of pGEX3x (Pharmacia Biotech Inc.) and
was designated pGSTE65. The same fragment of CSB was subcloned
into the EcoRI site of pMal-c2 to obtain pMALE65.
The CSA gene was subcloned from a human cDNA library by PCR
using primers 59-AGAATTCCCGGGATGCTGGGGTTTTTGTCCGCAC-
GCCAAACGGGTTT and 59-GTGAGATCTAGATATTCATCCTTCTTC-
ATCACTGCTGCTCCAGGCATC. These primers were made based upon
the published sequence of the CSA gene (11) and place EcoRI and SmaI
sites at the 59 border and BglII and XbaI sites at the 39 border of CSA.
The PCR product was subcloned into the pCRII vector (Invitrogen) to
give pCRCSA2. The SmaI-SpeI fragment of pCRCSA2 containing the
entire CSA gene was subcloned into the XmnI-XbaI site of pMal-c2 to
give pMALCSA.
The p2Bac vector (Invitrogen) was used to generate constructs for
expression of full-length CS proteins in Sf21 cells. The SmaI-HindIII
fragment of pCRCSA2 was inserted into the PvuII-HindIII site of p2Bac
to give pBacCSA, in which the CSA gene is downstream from the
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polyhedrin promoter. To construct a plasmid expressing both CSA and
CSB genes, the HpaI-XbaI fragment of pE6Hpa was inserted into the
SmaI-XbaI site of pBacCSA to obtain pBacCSAB, in which the CSB
gene is downstream from the p10 promoter. The Baculo Gold transfec-
tion kit (Pharmingen) was used to harvest recombinant viral stocks
expressing the CS genes.
Antibody Preparation—GST and MBP fusion proteins of CSA and
CSB were made in E. coli DR153 (recA3 DuvrB) and purified with
glutathione-Sepharose or amylose-agarose affinity resins (7). The CSA-
MBP protein was further purified using columns of DEAE-Sepharose,
Affi-Gel blue, and SP-Sepharose. To make anti-CSB antibodies, the
GST-CSB(528–1222) protein was first purified by glutathione-Sepha-
rose affinity chromatography and then by SDS-polyacrylamide gel elec-
trophoresis. The band containing the fusion protein was excised from
the gel, and the gel slice was ground into small pieces and injected into
a rabbit. To make an antibody affinity column, MBP-CSB(528–1222)
was covalently linked to SulfoLink coupling gel using the Pierce anti-
body immobilization kit. The immune serum was passed through the
column, and the anti-CSB antibodies were eluted from the column with
low pH into tubes containing 1 M TriszHCl, pH 8.0, and then dialyzed
against and stored in Manley buffer (25 mM HEPES pH 7.9, 12 mM
MgCl2, 0.5 mM EDTA, 2 mM dithiothreitol, and 17% glycerol) with 100
mM KCl.
During the purification of the MBP-CSA protein, approximately the
first half of the fusion protein eluted from the amylose resin as precip-
itate. This insoluble material was injected into a rabbit. An affinity
resin for purifying anti-CSA antibodies from the immune serum was
made by linking MBP-CSA to Affi-Gel-10 (Bio-Rad) as described by the
manufacturer.
Purification of CSB—Full-length CSB protein was purified from Sf21
cells using both Coomassie Blue staining and immunoblotting to locate
the fractions containing the protein. CSA was detected by immunoblot-
ting with anti-CSA antibodies. Approximately 2 liters of Sf21 cells at
approximately 106 cells/ml were infected with our recombinant baculo-
virus, which expresses CSA and CSB, and incubated at 26 °C for 42–48
h. The cells were collected by centrifugation, and CFE was prepared by
the procedure of Manley et al. (25). Most of the CSB and only a small
fraction of CSA were soluble. The CFE was passed through a DE52
column equilibrated with Manley buffer plus 100 mM KCl. The flow-
through that contained both proteins was applied to a SP-Sepharose
column equilibrated with Manley buffer plus 100 mM KCl. CSA was in
the flow-through of this column, but CSB was bound quantitatively.
The column was washed with 0.2 M KCl, and then a linear gradient of
0.2–1.0 M KCl in Manley buffer was applied. CSB eluted at about 0.4 M
KCl. Fractions containing CSB were pooled and diluted to a final
concentration of 0.1 M KCl in Manley buffer plus 0.01% Nonidet P-40.
The sample was applied to a single-stranded DNA cellulose column
equilibrated in the same buffer. The bound proteins were eluted with a
linear gradient of 0.1–1.0 M KCl in Manley buffer plus 0.01% Nonidet
P-40. CSB protein eluted at about 0.25 M KCl. Fractions containing CSB
were pooled and dialyzed against Buffer C (20 mM TriszHCl, pH 7.9, 0.1
mM EDTA, 19% glycerol, and 10 mM 2-mercaptoethanol) plus 0.3 M KCl.
Then, ammonium sulfate was added to 1.2 M, and the precipitate was
removed by centrifugation. The supernatant was applied to a phenyl
Superose 5/5 fast protein liquid chromatography column. The column
was washed with loading buffer, and bound proteins were eluted with a
linear gradient of 1.2 to 0.0 M ammonium sulfate in Buffer C. The CSB
eluted at about 0.1 M ammonium sulfate. The combined fractions were
dialyzed against Buffer C with 0.1 M KCl plus 0.01% Nonidet P-40 and
then applied to a Mono Q 5/5 fast protein liquid chromatography col-
umn. The column was washed, and then a gradient of 0.1–1.0 M KCl in
Buffer C plus 0.01%Nonidet P-40 was applied. CSB eluted at about 0.35
M KCl. Fractions were pooled, diluted to 0.12 M KCl in Buffer C plus
0.01% Nonidet P-40, and applied to a Mono S 5/5 column. A linear
gradient of 0.1–0.8 M KCl in Buffer C plus 0.01% Nonidet P-40 was
applied, and CSB eluted at about 0.45 M KCl. The pooled fractions were
diluted to 0.1 M KCl in Buffer C plus 0.01% Nonidet P-40 and applied to
a 0.4-ml column of Q-Sepharose. The protein bound quantitatively and
was eluted with 0.55 M KCl in Buffer C plus 0.01% Nonidet P-40.
Extract preparation and all chromatographic steps except the last were
performed in the presence of 1 mg/ml aprotinin and 1 mg/ml pepstatin A
(Boehringer Mannheim).
Transcription Proteins—RNA polymerase II was purified using
DE52, Mono Q, hydroxyapatite, and S300 columns. yTBP and recom-
binant TFIIB were gifts from Dr. D. Reinberg (Robert Wood Johnson
Medical School, Piscataway, NJ). TFIIE, in which the p56 subunit was
fused to MBP, was purified by amylose affinity chromatography. Re-
combinant TFIIF subunits were purified from E. coli and renatured as
described (22, 23). TFIIH was purified from HeLa CFE using DE52,
Affi-Gel blue, SP-Sepharose, S300, and Mono S columns. The E. coli
Mfd protein was purified as described previously (6); E. coli DNA
helicase II was the gift of Dr. S. Matson (University of North Carolina).
Methods—In vitro transcription-translation was performed with the
TNT-coupled reticulocyte lysate system from Promega.
ATPase, helicase, and DNA-binding assays were conducted in reac-
tion buffer that contained 40 mM HEPES, pH 7.9, 60 mM KCl, 8 mM
MgCl2, 2.4 mM dithiothreitol, 1.1 mM EDTA, and 6.8% glycerol. ATPase
assays were performed as described (26) except that the reaction con-
ditions were not restricted to hydrolysis of 15% of the substrate. For
antibody inhibition experiments, antibodies and the ATPases were
mixed in the reaction buffer and incubated on ice for 1 h before mixing
with ATP substrate. For gel shift analysis, DNA and protein were
incubated in 10 ml of reaction buffer at 30 °C for 30 min and then
separated on a 5% native polyacrylamide gel run at room temperature
at 60 V in 45 mM Tris borate and 0.5 mM EDTA, pH 8.3. Helicase assay
was conducted as described by Matson et al. (27), and the protein
pull-down assay was as described previously (7).
To examine ternary complex stability, we used template pMLU112,
which contains a “U-less cassette” as the first 112 bp of the transcrip-
tion unit (28). The plasmid was transcribed with a reconstituted human
RNA Pol II transcription system in the absence of UTP, producing a
stable, stalled RNA Pol II at the end of the cassette. The RNA was
labeled using a-32P-CTP. PvuII restriction endonuclease was then
added, and the mixture was incubated for 20 min at 32 °C to cleave the
DNA downstream from the stalled polymerase. Then, CS proteins were
added to the stalled polymerase complex in 31 mM HEPES, 6 mM
TriszHCl, pH 7.9, 120 mM KCl, 3.8 mM MgCl2, 2.1 mM EDTA, 3%
polyethylene glycol, 6.8% glycerol, and 208 mM each of ATP and GTP,
and 2 mM CTP. After 45 min at 32 °C the transcript was chased by
adding 400 mM UTP and 800 mM of cold CTP and incubating for 12 min.
RNA products were resolved on a 5% denaturing polyacrylamide gel.
RESULTS
Preparation of Anti-CSB and Anti-CSA Antibodies—To as-
sist in characterizing the CSB protein we prepared antibodies
against the putative catalytic region of the protein. This was
done by using as antigen a peptide containing the helicase
motifs region of CSB, amino acids 528-1222, fused to GST.
Immune serum was purified using an affinity column ligand
consisting of MBP fused to amino acids 528-1222 of CSB. Our
antibody was capable of detecting native CSB among the pro-
teins in CFE by Western analysis, although there was consid-
erable cross-reactivity (see below). The band identified as CSB
was absent when CS-B CFE was examined and when normal
human CFE was examined using preimmune serum. CSB
made by in vitro transcription-translation and by expression in
Sf21 cells was also detected with our antibody. Most impor-
tantly, the CSB protein expressed in Sf21 cells co-migrated
with native protein. In contrast, our anti-CSA antibody was of
poor quality in that Western analysis of CFE did not permit
identification of CSA protein among overwhelming cross-reac-
tivity. However, the anti-CSA antibodies did allow detection of
CSA overproduction in bacteria and Sf21 cells by immunoblot-
ting (data not shown).
Purification of CSB—Several approaches were taken to gen-
erate purified CSB protein for our investigations. The full-
length protein was not appreciably expressed in E. coli even
when fused to GST or MBP. Therefore we attempted to purify
CSB from HeLa CFE. However, after three or four chromato-
graphic steps, the protein consistently underwent extensive
degradation. Next, we attempted to overproduce the protein
using the baculovirus/Sf21 insect cell system. CSB protein was
greatly overproduced 24–48 h after infection of Sf21 cells with
our recombinant baculovirus. We were able to obtain about 30
mg of CSB of high purity from 2 3 109 cells after a seven-
column purification procedure. As seen in Fig. 1 the final step
contained a single band that was reactive with anti-CSB anti-
bodies. Even though the expression vector contained both CSA
and CSB genes, the majority of CSA protein was insoluble, and
the soluble fraction separated from the CSB protein completely
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in the second chromatographic step, suggesting that CSA and
CSB do not make a stable complex (data not shown). van Gool
(10) also found that CSA and CSB proteins readily separate
upon fractionation of cell extract, although it has been reported
that CSA and CSB can interact as revealed by immunoprecipi-
tation assays (11).
Functional Analysis of CSB—The prototype transcription-
repair coupling factor (TRCF) encoded by the E. coli mfd gene
possesses the so-called helicase motifs and is a DNA-independ-
ent ATPase and a DNA-binding protein with no detectable
helicase activity (6, 8). Because the putative human coupling
factor also possesses the helicase motifs, we decided to test the
purified CSB for ATPase, DNA-binding, and helicase activities.
CSB exhibited ATPase activity with a kcat ;3 min
21, which
increased to 45–53 min21 in the presence of single- or double-
stranded DNA (Table I). The ATPase activity is intrinsic to
CSB and is not due to a contaminating ATPase as evidenced by
the fact that anti-CSB antibodies specifically inhibited the
ATPase activity of CSB without affecting ATP hydrolysis by
Mfd or UvrD (helicase II), both of which also have helicase
motifs (Fig. 2). CSA-MBP did not exhibit ATPase activity and
did not affect the ATPase activity of CSB.
DNA binding was examined by gel shift assay using a 90-bp
DNA fragment. The results in Fig. 3 show that unlike Mfd
protein, CSB readily bound to DNA in the absence of nucleo-
tide. At low concentrations of CSB, a single retarded band was
detected, indicated as B1 in Fig. 3. At higher CSB concentra-
tions, there were apparently multiple CSB proteins bound per
duplex as indicated by the appearance of discreet lower mobil-
ity bands, labeled B2– B4. The presence of ATPgS increased the
amount of DNA bound by CSB. ATP and, to a lesser extent,
ATPgS decreased the number of CSB proteins/duplex. An al-
ternative explanation for B2–B4 is the formation of intermo-
lecular aggregates of B1.
Helicase activity was tested using as substrate a labeled
24-mer annealed to a circular, single-stranded DNA molecule.
Even though CSB binds to DNA and exhibits DNA-stimulated
ATPase activity, Fig. 4 shows that CSB cannot displace the
24-mer, whereas helicase II releases it quantitatively. CSA-
MBP did not exhibit helicase activity and did not confer heli-
case activity to CSB. Thus we conclude that CSB, like its E. coli
and Saccharomyces cerevisiae counterparts Mfd (6) and Rad 26
(18), respectively, is a protein with helicase motifs but no
helicase activity.
Interactions of CSB with Transcription and Repair Pro-
teins—The Mfd protein brings about transcription-coupled re-
pair by interacting with RNA Pol stalled at a lesion and then
removing the polymerase and directing the damage recognition
subunit of the bacterial excision nuclease to the lesion (6–8).
Similarly, it has been found that CSB interacts with CSA and
TABLE I
DNA-stimulated ATPase activity of CSBa







a ds, double-stranded; ss, single-stranded.
FIG. 1. CSB protein purified from Sf21 cells. A sample from the
last chromatographic step was resolved by SDS-polyacrylamide gel
electrophoresis, and proteins were analyzed by Coomassie Blue stain-
ing in lane 1 and immunoblotting in lane 2. CSB migrates slightly
slower than the 175-kDa prestained marker (MBP-b-galactosidase)
even though its size, based upon its sequence, is 168 kDa (12). The
native human protein and the CSB from Sf21 cells had the same
mobility.
FIG. 2. ATPase activity of CSB is inhibited by anti-CSB anti-
body. CSB (100 ng), Mfd (1.2 mg), and DNA helicase II (87 ng) were
incubated with and without anti-CSB antibody, and then the amount of
ATP hydrolyzed by the proteins was measured after a 2-h incubation.
Single-stranded M13 DNA (150 ng) was included in the hydrolysis
reactions of CSB and DNA helicase II. The background level of hydrol-
ysis observed in the absence of protein (8–11%) has been subtracted
from the values shown. The antibody preparation did not hydrolyze
ATP. The DNA-independent ATPase activity of CSB was also inhibited
by anti-CSB antibodies (data not shown).
FIG. 3. CSB DNA binding detected by gel shift assay. Various
amounts of CSB were incubated with a 90-bp DNA duplex in the
presence of combinations of ATP and ATPgS, as indicated in the figure.
Free and protein-bound DNA were separated on a 5% gel. CSB bound
even in the absence of nucleotide, and binding was stimulated by
ATPgS. Free DNA (F) is indicated as are four discrete bands of protein-
bound DNA (B1–B4).
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with the XPG protein (29) and that CSA interacts with the p44
subunit of TFIIH (11), suggesting that a related mechanism
may be operative in humans. We wished to know if CSB exhib-
ited binding and functional properties similar to those of Mfd,
in particular binding to the damage recognition protein and
disruption of the stalled RNA Pol complex.
First, we have found that CSB interacts with TFIIH as
shown in Fig. 5A. Furthermore, because the fusion protein used
in this assay comprised only amino acids 528-1222 of CSB, our
result narrows down the interaction site to this domain. TFIIH
is both a transcription and an excision repair factor; in tran-
scription, it facilitates initiation of RNA synthesis in conjunc-
tion with TFIIE (30, 31). However, in transcription-indepen-
dent excision repair TFIIH functions independently of TFIIE,
and no effect of TFIIE on this mode of repair could be detected
(32). However, because CSB is presumed to act at the tran-
scription/repair interface, we considered the possibility that it
may interact with TFIIE. Interestingly, we found that CSB
binds to TFIIE, and the binding is mediated by the p34 subunit
(Fig. 5, B and C). Finally, because a working model for coupling
presupposes the recruitment of damage recognition proteins by
CSB, we tested for binding to XPA. Fig. 5D shows that XPA
specifically binds to CSB, consistent with CSB being a bridge
between transcription and repair proteins.
Effect of CSB on Stalled RNA Pol II—A striking feature of
transcription-repair coupling in E. coli is the removal of stalled
RNA Pol by the Mfd protein (6). Mfd removes RNA Pol stalled
at a lesion, stalled by nucleotide starvation, or blocked by a
DNA-bound protein (8). We tested CSB for an analogous activ-
ity. RNA Pol II was stalled 112 nucleotides into a U-less cas-
sette by omission of UTP, and then the ternary complex was
incubated with CS proteins. With this experimental setup, the
subsequent addition of UTP leads to elongation of RNA to the
end of the template (Fig. 6, lanes 1 and 2) in the absence of
other factors. We found that incubation with CSB and CSA by
themselves or in combination does not interfere with the sub-
sequent formation of runoff transcripts (Fig. 6, lanes 3, 5, and
7 versus lanes 4, 6, and 8). Thus, CSB clearly does not release
stalled RNA Pol II.
DISCUSSION
Transcription-repair coupling occurs in many organisms, in-
cluding prokaryotes and eukaryotes. Initial biochemical inves-
tigations of this phenomenon revealed that in E. coli, a TRCF
encoded by the mfd gene was required and sufficient to couple
the transcription and repair processes. It did so by removing
FIG. 5.CSB can interact with TFIIH, TFIIE, and XPA. Pull-down
assays were performed to examine the possible protein-protein interac-
tions of CSB. For panel A, we used GSTE65 in which GST was fused to
amino acids 528-1222 of CSB. GST and GSTE65 were coupled to glu-
tathione-Sepharose resin, and then the resins were incubated with
HeLa CFE. After incubation and pelleting, the free proteins (F) in the
supernatant were recovered, and the resin-bound proteins (B) were
recovered after washing the resin. Fractions were resolved by SDS-
polyacrylamide gel electrophoresis, and a Western blot of the gel hy-
bridized with anti-XPB antibody is shown. It is possible that the TFIIH-
CSB interaction shown in panel A is mediated by CSA because CSA has
been reported to interact with both CSB and TFIIH (11). Panels B and
C show experiments with the p34 and p56 subunits of TFIIE. In panel
B, three resins were used: GST, GST-p56, and GST-p56 bound to p34
(TFIIE). These resins were incubated with HeLa CFE, and free and
bound fractions were examined by Western blot using anti-CSB anti-
bodies. There is a strongly cross-reacting, unidentified protein of about
145 kDa in size that did not bind to any of the resins. CSB bound to the
resin only when p34 was present. In panel C, we used glutathione-
Sepharose bound to either GST or GST-p34. 35S-labeled CSB protein
made with an in vitro transcription-translation system was applied to
the resins, and the presence of CSB in free and bound fractions was
detected with the autoradiograph shown. In panel D, 35S-labeled CSB
was applied to either GST or GST-XPA resins, and the autoradiograph
shows the presence of CSB in the free and bound fractions.
FIG. 6. CSB does not remove stalled RNA Pol II from the tem-
plate. Radiolabeled transcripts were made in the absence of UTP using
pMLU112 as template with a reconstituted RNA Pol II transcription
system. The principal product (labeled Stalled) is a 112-nucleotide
transcript formed when RNA Pol II stalls at the end of the U-less
cassette of pMLU112. These complexes were then digested with PvuII,
which cleaves downstream of the stall site, and then incubated with
combinations of CSB and CSA-MBP proteins. Then, in the even-num-
bered lanes, reactions were chased by incubation with UTP to allow
transcription to the end of the template plus cold CTP to dilute the
radiolabel, and the products were separated on the 5% sequencing gel
shown. Runoff indicates the products of transcription to the end of the
templates. The bands longer than stalled transcript in the absence of
chase are presumably due to minor contamination of one or more of the
three rNTPs with UTP.
FIG. 4. CSB lacks helicase activity. Various amounts of CSB were
incubated with single-stranded pPU192 circular DNA annealed to a
32P-labeled 24-mer. Substrate and product were separated with a 10%
polyacrylamide gel. The mobility of the 24-mer released by either heat
treatment (lane 2, 95° C, 5 min) or DNA helicase II (Hel II) is indicated.
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the stalled RNA Pol and delivering the repair proteins to the
lesion at an accelerated rate compared to lesions in which
polymerase was not stalled (6). A protein from Bacillus subtilis
was found to have similar structure and function, notably, a
region containing the seven so-called helicase motifs, and the
ability to remove a stalled RNA Pol (33). Based on genetic data
and in vivo studies, humans require two proteins for transcrip-
tion-repair coupling, the CSA and CSB proteins (5). CSA is a
member of the “WD-repeat” family of proteins, which so far
have been found to have structural and regulatory roles but no
enzymatic activity (11, 13). CSB (12) and its yeast homolog,
Rad26 (34), are clearly more similar to the prokaryotic coupling
factors than CSA. The properties of these four TRCFs are
summarized in Table II.
Aside from having identical cellular functions, the TRCFs in
Table II are similar in being relatively large and possessing the
helicase motifs. Although all four proteins can bind to DNA and
hydrolyze ATP, none exhibit detectable helicase activity. This
property may not be unique to this class of enzymes because
two other proteins with helicase motifs, SNF2 (35) and Rad5
(36), have also been reported to lack helicase activity.
In those cases in which protein-protein interactions have
been investigated, TRCFs have been found to associate with
various transcription and nucleotide excision repair proteins
(Table II). Although these interactions are valuable toward
devising models and working hypotheses, with the human pro-
teins they have been largely identified by assays designed to
detect weak protein-protein interactions. The prokaryotic in-
teractions listed are more likely to reflect functional interac-
tions because they have been corroborated by independent
approaches. However, in no case have transcription or repair
proteins been found to form a tight complex with a TRCF.
Previous studies have indicated that DNA binding and ATP
hydrolysis by E. coliMfd protein are involved in dissociation of
stalled RNA Pol. It was inferred that the Mfd protein must bind
nucleotide to bind to DNA and that hydrolysis of nucleotide is
associated with dissociation of Mfd from DNA. It was proposed
that, for dissociation of stalled RNA Pol, first Mfd-ATP binds to
the ternary complex, both to the DNA and to RNA Pol. Then,
hydrolysis of ATP brings about the release of Mfd from DNA
together with the associated RNA Pol (7). CSB is strikingly
different from Mfd in both DNA binding (ATPgS-independent)
and ATP hydrolysis (strongly stimulated by DNA). Thus it is
not surprising that CSB, in contrast to Mfd, does not function
to remove its cognate stalled RNA Pol from DNA.
A most interesting aspect of transcription-repair coupling is
the reaction mechanisms and in particular the disposition of
the RNA Pol stalled at the lesion. In E. coli, RNA Pol stalled at
the lesion inhibits repair, and Mfd removes it. Mfd also binds to
the repair enzyme, which is delivered to the transcription-
blocking lesion at an accelerated rate (6, 37). In humans, RNA
Pol stalled at a lesion does not inhibit repair,2 and CSB does
not remove the stalled polymerase. CSB does, however, bind to
repair proteins and may, like Mfd, function to deliver them to
the transcription-blocking lesion at an accelerated rate. Such a
mechanism, in which RNA Pol is not removed from the tem-
plate during repair, could permit subsequent transcription by
the polymerase without reinitiation at the promoter, as de-
scribed by Hanawalt (16).
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